Trial · NCT07453095
Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
NCT07453095, Phase 2, Recruiting, Fondazione Italiana Linfomi - ETS
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy. Trials, record NCT07453095. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07453095
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy
- NCT number
- NCT07453095
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 41 participants, estimated
- Lead sponsor
- Fondazione Italiana Linfomi - ETS
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Glofitamab
- First posted
- 2026-03-05
- Last updated
- 2026-06-25
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Complete Response Rate (CRR) | 27 months | Complete Response Rate (CRR) at the end of treatment (C12) (assessed by the independent review committee according to Lugano 2014 criteria) and at any time during study treatment. |
| Secondary | Overall Response Rate (ORR) | 27 months | Overall Response Rate (ORR) defined as the proportion of patients achieving either a Complete Response (CR) or Partial Response (PR) (assessed by the independent review committee according to Lugano 2014 criteria), and evaluated at C6 and C12. |
| Secondary | Progression Free Survival (PFS) | 51 months | Progression Free Survival (PFS) defined as the time from the study inclusion to disease progression or death from any cause. |
| Secondary | Overall Survival (OS) | 51 months | Overall Survival (OS) defined as the time between the study inclusion and death from any cause. |
| Secondary | Duration of Response (DOR) | 51 months | Duration of Response (DOR) defined as the time from the first documentation of tumor response (Complete or Partial Response) to disease progression or death. |
| Secondary | Time to Next Treatment (TTNT) | 51 months | Time to Next Treatment (TTNT) defined as the time represents the interval from the study inclusion to initiation of the next line of therapy. |
| Secondary | Event Free Survival (EFS) | 51 months | Event Free Survival (EFS) defined as the time from the study inclusion to disease progression, death, or Next Anti-Lymphoma Treatment (NALT) start. |
| Secondary | AEs | 51 months | Frequency and severity of adverse events (AEs) classified as per CTCAE (Common Terminology Criteria for Adverse Events) latest version and SAE. |
| Other | MRD evaluation PCR (RQ-PCR) and NGS | 33 months | MRD will be analyzed using both quantitative real-time PCR (RQ-PCR) and nextgeneration sequencing (NGS) on BM, PB and plasma samples using the most validated Euro-MRD standardized procedures |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07453095
GET https://conductscience.org/api/trials/v1/NCT07453095/registered